Breast cancer risk assessment in a mammography screening program and participation in the IBIS-II chemoprevention trial

Breast Cancer Research and Treatment

Volumn 121, Issue 1, 2010, Pages 101-110

  Loehberg, Christian R ^a   Jud, Sebastian M ^a   Haeberle, Lothar ^a   Heusinger, Katharina ^a   Dilbat, Gerhard ^f   Hein, Alexander ^a   Rauh, Claudia ^a   Dall, Peter ^c   Rix, Nadine ^a   Heinrich, Sabrina ^a   Buchholz, Stefan ^d   Lex, Benno ^b   Reichler, Barbara ^e   Adamietz, Boris ^a   Schulz Wendtland, Ruediger ^a   Beckmann, Matthias W ^a   Fasching, Peter A ^g  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b INSTITUTE OF PATHOLOGY   (Germany)

^c Klinikum Lueneburg   (Germany)

^d CARITAS KRANKENHAUS ST JOSEF   (Germany)

^e Radiology Center Erlangen   (Germany)

^f Radiology Center Roth and Weissenburg   (Germany)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer risk; Chemoprevention trial; IBIS II; Mammography screening; Patient recruitment

Indexed keywords

ANASTROZOLE; PLACEBO;

ADULT; AGE; AGED; ARTICLE; BODY MASS; BREAST CANCER; BREAST SURGERY; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; FAMILY HISTORY; FAMILY SIZE; FEMALE; GERMANY; HEALTH PROGRAM; HORMONE SUBSTITUTION; HUMAN; INDIVIDUALIZATION; INTERPERSONAL COMMUNICATION; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MEDICAL INFORMATION; PATIENT ATTITUDE; PATIENT PARTICIPATION; PRIORITY JOURNAL; QUESTIONNAIRE; REFUSAL TO PARTICIPATE; RISK ASSESSMENT;

AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOPREVENTION; DOUBLE-BLIND METHOD; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; NITRILES; PATIENT SELECTION; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SOCIOECONOMIC FACTORS; TRIAZOLES;

EID: 77951295037     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0845-8     Document Type: Article

References (43)

1. J Cuzick J Forbes R Edwards, et al. 2002 First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial Lancet 360 817 824 10.1016/S0140-6736(02)09962-2 1:CAS:528: DC%2BD38XntVWmsrg%3D 12243915 (Pubitemid 35257944)
2. B Fisher JP Costantino DL Wickerham, et al. 1998 Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst 90 1371 1388 10.1093/jnci/90.18.1371 1:CAS:528:DyaK1cXmtlelurs%3D 9747868
3. T Powles R Eeles S Ashley, et al. 1998 Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial Lancet 352 98 101 1:CAS:528:DyaK1cXkvVeht7w%3D 9672274
4. U Veronesi P Maisonneuve V Sacchini N Rotmensz P Boyle 2002 Tamoxifen for breast cancer among hysterectomised women Lancet 359 1122 1124 10.1016/S0140-6736(02)08159-X 1:CAS:528:DC%2BD38Xis1ehsL0%3D 11943263 (Pubitemid 34270739)
5. J Cuzick T Powles U Veronesi, et al. 2003 Overview of the main outcomes in breast-cancer prevention trials Lancet 361 296 300 10.1016/S0140-6736(03) 12342-2 1:STN:280:DC%2BD3s%2FltVCmsA%3D%3D 12559863 (Pubitemid 36126189)
6. JA Cauley L Norton ME Lippman, et al. 2001 Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation Breast Cancer Res Treat 65 125 134 10.1023/A:1006478317173 1:CAS:528:DC%2BD3MXisVCjur4%3D 11261828 (Pubitemid 32193616)
7. VG Vogel JP Costantino DL Wickerham, et al. 2006 Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 295 2727 2741 10.1001/jama.295.23.joc60074 1:CAS:528:DC%2BD28XmtFOltLc%3D 16754727
8. PE Goss JN Ingle S Martino, et al. 2003 A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer N Engl J Med 349 1793 1802 10.1056/NEJMoa032312 1:CAS:528:DC%2BD3sXosl2gtbc%3D 14551341 (Pubitemid 37362955)
9. M Baum AU Budzar J Cuzick, et al. 2002 Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial Lancet 359 2131 2139 10.1016/S0140-6736(02)09088-8 1:CAS:528:DC%2BD38XkslGhsLY%3D 12090977 (Pubitemid 34694019)
10. B Thurlimann A Keshaviah AS Coates, et al. 2005 A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer N Engl J Med 353 2747 2757 10.1056/NEJMoa052258 16382061 (Pubitemid 43016814)
11. RC Coombes E Hall LJ Gibson, et al. 2004 A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 1081 1092 10.1056/NEJMoa040331 1:CAS:528:DC%2BD2cXitV2qtbc%3D 15014181 (Pubitemid 38298988)
12. R Jakesz W Jonat M Gnant, et al. 2005 Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial Lancet 366 455 462 10.1016/S0140-6736(05)67059-6 1:CAS:528:DC%2BD2MXntVeisLw%3D 16084253 (Pubitemid 41111693)
13. H Mouridsen A Giobbie-Hurder A Goldhirsch, et al. 2009 Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer N Engl J Med 361 766 776 10.1056/NEJMoa0810818 1:CAS:528:DC%2BD1MXhtVWls7fM 19692688
14. JF Forbes J Cuzick A Buzdar A Howell JS Tobias M Baum 2008 Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial Lancet Oncol 9 45 53 10.1016/S1470-2045(07) 70385-6 18083636
15. RC Coombes LS Kilburn CF Snowdon, et al. 2007 Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial Lancet 369 559 570 10.1016/S0140-6736(07)60200-1 1:CAS:528:DC%2BD2sXhvVGgsro%3D 17307102
16. J Cuzick 2003 Aromatase inhibitors in prevention-data from the ATAC (Arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study) Recent Results Cancer Res 163 96 103 1:CAS:528:DC%2BD3sXmsFOhu7w%3D 12903846 (discussion 264-266)
17. PE Goss H Richardson R Chlebowski, et al. 2007 National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: evaluation of exemestane to prevent breast cancer in postmenopausal women Clin Breast Cancer 7 895 900 10.3816/CBC.2007.n.057 1:CAS:528:DC%2BD1cXhtlyntLw%3D 18269782
18. Editorial (2007) NCI and the STELLAR trial. Lancet 369:2134
19. BK Dunn A Ryan 2009 Phase 3 trials of aromatase inhibitors for breast cancer prevention: following in the path of the selective estrogen receptor modulators Ann N Y Acad Sci 1155 141 161 10.1111/j.1749-6632.2009.03688.x 1:CAS:528:DC%2BD1MXktFKltrw%3D 19250201
20. TJ Powles 2002 Breast cancer prevention Oncologist 7 60 64 10.1634/theoncologist.7-1-60 11854547 (Pubitemid 34151108)
21. S Vescia G von Minckwitz S Loibl, et al. 2008 The GISS Trial: a pilot phase randomized prevention trial of screening plus goserelin plus ibandronate, versus screening alone in premenopausal women at increased risk of breast cancer (abstract) Eur J Cancer 6 72
22. GPB von Minckwitz K Hofmann, et al. 2002 Prevention with goserelin and ibandronate in premenopausal women with familial breast cancer risk: first experiences of the GISS study (abstract) Arch Gynecol Obstet 267 Suppl 1 S52
23. D Evans F Lalloo A Shenton C Boggis A Howell 2001 Uptake of screening and prevention in women at very high risk of breast cancer Lancet 358 9285 889 890 10.1016/S0140-6736(01)06039-1 1:STN:280:DC%2BD3Mrit1ehtA%3D%3D 11567707 (Pubitemid 32900574)
24. R Schulz-Wendtland N Becker K Bock K Anders W Bautz 2007 Mammography screening Radiologe 47 359 369 10.1007/s00117-007-1490-z 1:STN:280: DC%2BD2szotFWhuw%3D%3D 17375277 (quiz 70) (Pubitemid 46631899)
25. Kooperationsgemeinschaft-Mammographie (2009) Evaluationsbericht 2005-2007: Ergebnisse des Mammographie-Screening-Programms in Deutschland 2009. www.mammo-programm.de/fachinformationen/evaluation.php
26. J Tyrer SW Duffy J Cuzick 2004 A breast cancer prediction model incorporating familial and personal risk factors Stat Med 23 1111 1130 10.1002/sim.1668 15057881 (Pubitemid 38477070)
27. PA Fasching G von Minckwitz T Fischer, et al. 2007 The impact of breast cancer awareness and socioeconomic status on willingness to receive breast cancer prevention drugs Breast Cancer Res Treat 101 95 104 10.1007/s10549-006- 9272-2 17033928 (Pubitemid 47555333)
28. The Million Women Study Collaborative Group 1999 The Million Women Study: design and characteristics of the study population. The Million Women Study Collaborative Group Breast Cancer Res 1 73 80 10.1186/bcr16 (Pubitemid 32223549)
29. The Women's Health Initiative Study Group 1998 Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group Control Clin Trials 19 61 109 10.1016/S0197-2456(97) 00078-0 (Pubitemid 28085557)
30. A Yeomans-Kinney SW Vernon RF Frankowski DM Weber JM Bitsura VG Vogel 1995 Factors related to enrollment in the breast cancer prevention trial at a comprehensive cancer center during the first year of recruitment Cancer 76 46 56 10.1002/1097-0142(19950701)76:1<46::AID-CNCR2820760107>3.0.CO;2-B 1:STN:280:DyaK283it12ruw%3D%3D 8630876
31. JE Rossouw GL Anderson RL Prentice, et al. 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial JAMA 288 321 333 10.1001/jama.288.3.321 1:CAS:528:DC%2BD38Xltlegs7k%3D 12117397
32. SR Majumdar EA Almasi RS Stafford 2004 Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative JAMA 292 1983 1988 10.1001/jama.292.16.1983 1:CAS:528:DC%2BD2cXptVeksb8%3D 15507584 (Pubitemid 39411207)
33. V Beral 2003 Breast cancer and hormone-replacement therapy in the Million Women Study Lancet 362 419 427 10.1016/S0140-6736(03)14596-5 1:CAS:528:DC%2BD3sXmt1ajsrw%3D 12927427
34. RT Chlebowski LH Kuller RL Prentice, et al. 2009 Breast cancer after use of estrogen plus progestin in postmenopausal women N Engl J Med 360 573 587 10.1056/NEJMoa0807684 1:CAS:528:DC%2BD1MXhsFyiur8%3D 19196674
35. MH Gail LA Brinton DP Byar, et al. 1989 Projecting individualized probabilities of developing breast cancer for white females who are being examined annually J Natl Cancer Inst 81 1879 1886 10.1093/jnci/81.24.1879 1:STN:280:DyaK3c%2FnvF2kuw%3D%3D 2593165
36. EB Claus N Risch WD Thompson 1994 Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction Cancer 73 643 651 10.1002/1097-0142(19940201)73:3<643::AID-CNCR2820730323>3.0.CO;2-5 1:STN:280:DyaK2c7jtVagug%3D%3D 8299086
37. G Parmigiani D Berry O Aguilar 1998 Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2 Am J Hum Genet 62 145 158 10.1086/301670 1:CAS:528:DyaK1cXhsVGrsrc%3D 9443863 (Pubitemid 28093844)
38. AC Antoniou PP Pharoah P Smith DF Easton 2004 The BOADICEA model of genetic susceptibility to breast and ovarian cancer Br J Cancer 91 1580 1590 1:CAS:528:DC%2BD2cXotlCkur8%3D 15381934
39. PA Fasching MR Bani C Nestle-Kramling TC Goecke D Niederacher MW Beckmann MP Lux 2007 Evaluation of mathematical models for breast cancer risk assessment in routine clinical use Eur J Cancer Prev 16 216 224 10.1097/CEJ. 0b013e32801023b3 17415092 (Pubitemid 46597425)
40. NF Boyd H Guo LJ Martin, et al. 2007 Mammographic density and the risk and detection of breast cancer N Engl J Med 356 227 236 10.1056/NEJMoa062790 1:CAS:528:DC%2BD2sXnslSjsg%3D%3D 17229950 (Pubitemid 46143226)
41. JA Tice SR Cummings R Smith-Bindman L Ichikawa WE Barlow K Kerlikowske 2008 Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model Ann Intern Med 148 5 337 347 18316752
42. J Chen D Pee R Ayyagari B Graubard C Schairer C Byrne J Benichou MH Gail 2006 Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density J Natl Cancer Inst 98 17 1215 1226 16954474
43. SR Cummings JA Tice S Bauer WS Browner J Cuzick E Ziv V Vogel J Shepherd C Vachon R Smith-Bindman, et al. 2009 Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk J Natl Cancer Inst 101 6 384 398 10.1093/jnci/djp018 19276457